Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

AMG 145: Phase III

Treating: Cardiac
Indication: Dyslipidemia
Status: Not Currently Enrolling

A double blind, randomized, placebo-controlled, multicenter study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease

ATB200-02: Phase I/II

Treating: Pompe Disease
Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III

Treating: Axial Spondyloarthritis
Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Enrolling

A randomized, double-blind, placebo-controlled multicenter
study of secukinumab to evaluate the safety, tolerability
and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CIRT: Cardiovascular Inflammation Reduction Trial

Treating: Cardiac
Status: Open and Currently Enrolling

A randomized, double-blind placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.

CLEE011A2404: Phase IIIb

Treating: Advanced Breast Cancer
Indication: Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer
Status: Open and Currently Enrolling
COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

D1699C00001: Phase III

Treating: Heart Failure
Indication: Chronic Heart Failure with Reduced Ejection Fraction
Status: Open/Currently Enrolling
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction


Treating: Cardiac

Treating: Cardiac
Status: Not Currently Enrolling

A multicenter, randomized, double blind, placebo-controlled trial to evaluate the effect of Dapagliflozin 10mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes.

DIV-SCLC-301: Phase II/III

Treating: Lung Cancer
Indication: Small Cell Lung Cancer
Status: Open/Currently Enrolling

A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer

Novartis: Phase IV

Treating: Acromegaly
Status: Open and Currently Enrolling

A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s Disease or Acromegaly.

Meet Our Providers

Brian Thomas, MD

Ambulatory Surgery Center


Erica Bonilla, DPT

Physical Therapy